Equivalency Studies Of Biosimilar Monoclonal Antibodies using Carterra’s HT-SPR at Bio-Techne

Summary

Bio-Techne leverages the decades of experience of R&D Systems’ antibody manufacturing to support both research and diagnostic communities with high-quality, reliable antibodies. Bio-Techne’s expertise spans the spectrum from de novo antibody engineering to recombinant antibody conversion. We’ve taken this engineering know-how and deployed it to bring you a range of biosimilar monoclonal antibodies for research use. Bio-Techne’s biosimilar antibodies are manufactured from publicly available sequences, with no alteration or truncation. In this whitepaper, we demonstrate that Bio-Techne’s biosimilar antibodies, intended for ex vivo research use only, are equivalent to the original therapeutic antibodies in functionality and kinetics, as well as surface charge.